podcasts Ratings /ratings/en/research-insights/podcasts/2020-09-21-the-sp-pharma-dose-episode-36-what-bausch-remainco-s-credit-quality-post-spinoff-could-look-like content esgSubNav
In This List

The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

NEWS

As The Escrow Flies: China Developers Navigate Convoluted Rules On Presales

Capital Markets View - January 2022

COMMENTS

Strong Fundamentals In U.S. Tech Allow Capital Allocation Flexibility

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

Listen: The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back